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Abstract Functional neuroendocrine tumors are often low-
grade malignant neoplasms that can be cured by surgery if
detected early, and such detection may in turn be accelerated
bythe recognition of neuropeptide hypersecretionsyndromes.
Uniquely, however, relief of peptic symptoms induced by
hypergastrinemia is now available from acid-suppressive
drugs such as proton-pump inhibitors (PPIs). Here we
describe a clinical case in which time to diagnosis from the
onset of peptic symptoms was delayed more than 10 years, in
part reflecting symptom masking by continuous prescription
of the PPI omeprazole. We propose diagnostic criteria for this
under-recognized new clinical syndrome, and recommend
that physicians routinely measure serum gastrin levels in
persistent cases of PPI-dependent dyspepsia unassociated
with H. pylori.
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Abbreviations
PNET pancreatic neuroendocrine tumour
PPI proton pump inhibitor
ZES Zollinger–Ellison syndrome
Background
Pancreatic neuroendocrine tumors (PNETs) are generally
characterised by slow onset of non-specific symptoms and
consequent delay in diagnosis. With specific reference to
gastrinomas, Ellison & Sparks showed in a prospective
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although highly effective symptomatic therapy for the
neuroendocrine symptoms of gastrinoma—has been asso-
ciated with upstaging of malignant disease at diagnosis [1].
A retrospective analysis reached the same conclusion based
on correlations of case referral patterns over time [2];
however, the expected secondary incidence rise following
diagnostic delay was not confirmed, casting doubt on a
causal interpretation. Confusingly, in the largest clinical
analysis of Zollinger–Ellison syndrome ever published, this
same group reported no change in age of onset, delay in
diagnosis (about 5 years) or frequency of complications
following introduction of PPIs [3]. Since these negative
conclusions could plausibly have been confounded by
concurrent improvements in diagnostic technology and/or
physician awareness, we present here an instructive case
of malignant gastrinoma that clearly illustrates how a
suboptimal index of suspicion can delay diagnosis to
more than 10 years after the first presentation of reflux
symptoms managed with PPIs.
Case Presentation
A 58-year-old Caucasian male presented in 2000 with a long
history of gastroesophageal reflux symptoms since the
1990s; his past history was notable for hypertension and
appendicectomy, and his family history was negative. Upper
endoscopy showed gastroesophageal reflux disease, and a
segment of Barrett’s esophagus was confirmed by biopsy.
He was treated initially with the H2-receptor antagonist
ranitidine, but this was soon changed to the PPI omeprazole
(20 mg/day) due to inadequate pain control. His symptoms
briskly recurred on discontinuing omeprazole, leading to
indefinite continuation of this medication as long-term
maintenance. Upper endoscopy was repeated every 2 years
for monitoring. In 2001 the symptom complex evolved to
include recurrent episodic abdominal pain of cramping
nature associated with retching and prominent borborygmi.
Diarrhea was not a feature; instead, constipation was
reported, with abdominal X-rays showing subacute intestinal
obstruction. Colonoscopy was unremarkable. The patient
was followed up in a primary healthcare setting.
In March 2004 he presented again, this time with
subacute right upper quadrant pain. A contrast magnetic
resonance imaging (MRI) scan of the hepatobiliary system
revealed no abnormality apart from two small liver nodules,
measuring 11 mm in segment VI, and 20 mm in segment
VII, respectively, which were hypointense on plain T1-
weighted images, and hyperintense with a ‘light-bulb’
appearance on plain T2-weighted images (Fig. 1a), with
peripheral enhancement and central filling-in on post-
contrast T1-weighted images. The radiological features
were deemed typical of hemangiomas, so no biopsy was
advised. Maintenance omeprazole was increased to 20 mg
twice-daily, and the pain resolved.
In 2007 the patient underwent a further reassessment for
recurrent episodic abdominal discomfort. Upper endoscopy
at this time confirmed persistent esophagitis with no frank
ulceration; the previous changes of Barrett’s esophagus had
resolved on long-term PPI. In January 2008 he was
admitted to a tertiary referral centre for an acute exacerba-
tion of abdominal pain. Physical examination revealed a
febrile patient with mild tenderness over the right lower
Fig. 1 a MRI liver in 2004 showing one of the lesions which was
hyperintense with a typical ‘light-bulb’ appearance on plain T2-
weighted images. b FDG-PET scan showing uptake in the liver and
pancreatic lesions with regional lymph node involvement. c Octreo-
Scan confirming metastatic pancreatic neuroendocrine tumor
88 H. Wong et al.quadrant. Routine blood tests revealed a raised white cell
count of 11.4x10
9/L (normal: 4.4–10.1x10
9/L) with neu-
trophilia, normal renal function and electrolytes including
calcium; mildly elevated serum alkaline phosphatase of 123
U/L (normal: 42–110 U/L) and aspartate transaminase of
55 U/L (normal: 15–38 U/L), and normal bilirubin and
clotting profile. Plain abdominal X-ray revealed a fecal-
loaded colon with prominent small bowel loops. Computed
tomography (CT) of the abdomen and pelvis was performed
to exclude diverticulitis; this revealed a 10 cm heterogenous
mass spanning segments V, VI, VII and VIII of the right
lobe of the liver, a second intrahepatic mass occupying
segments VI and VII adjacent to it, and a pancreatic mass at
the uncinate process with regional mesenteric lymphade-
nopathy. Tumor markers including alpha-fetoprotein (AFP),
prostate specific antigen (PSA) and Ca 19.9 were normal;
carcinoembryonic antigen (CEA) was slightly raised to
7.4 ng/ml (normal: < 5 ng/ml). The patient then underwent
positron emission tomography/computed tomography
(PET-CT) with 18-fluorodeoxyglucose (FDG), which
showed hypermetabolic lesions in the liver, pancreas and
mesenteric lymph nodes (Fig. 1b). Ultrasound-guided
biopsy of the liver mass confirmed a low-grade neuroen-
docrine tumor; immunohistochemistry for synaptophysin,
chromogranin and CD56 was positive. Other markers,
including inhibin, c-kit, AFP, HEPA, CK7 and CK20, were
negative.
Further neuroendocrine workup was performed after
stopping PPI for two weeks. Fasting serum gastrin
remained elevated (240 pg/ml; normal <113 pg/ml), with
less marked elevations of chromogranin A (247 ng/ml;
normal <160 ng/ml), and somatostatin (25 pg/ml; normal
<22 pg/ml). Fasting plasma glucose, insulin, C-peptide
and glucagon, and urinary vanillylmandelic acid (VMA)
and catecholamines were normal, but 24-hour urinary
5-hydroxyindoleacetic acid was raised. Gastric acid
output studies were not performed. Somatostatin recep-
tor imaging (OctreoScan) showed intense uptake in the
uncinate process of the pancreas, and in the right lobe,
segment II, III and caudate lobe of liver, compatible
with a neuroendocrine tumor rich in somatostatin receptors
(Fig. 1c).
In March 2008 the patient underwent the first of two
laparotomies. Because of the symptomatic nature of the
large hepatic metastases, partial hepatectomy was per-
formed first. A 10 cm tumor was found in the right lobe
of the liver, and smaller tumors were found in segment II
and III; right hepatectomy was carried out with wedge
resection of the segment II lesion, radiofrequency ablation
of the segment III lesion, followed by wedge resection of
segment III. Histopathologic examination confirmed a
metastatic well-differentiated neuroendocrine tumor of low
grade malignancy. Expression of the proliferation marker
MIB-1 (Ki-67) was less than 5%. As expected, immuno-
histochemical studies were positive for chromogranin,
synaptophysin, CD56, serotonin and gastrin.
Whipple’s pancreatectomy and anastomosis was per-
formed six weeks later, and a 5 cm uncinate process
primary pancreatic islet-cell tumor removed. Pathology
showed a well-differentiated pancreatic neuroendocrine
tumor with lymphovascular permeation and regional lymph
node metastases; immunohistochemical staining again
confirmed the positivity of neuroendocrine markers
(Fig. 2). Based on the symptom diathesis, biochemical
analyses and histopathological findings, a clinical diagnosis
of malignant pancreatic gastrinoma was made. Post-surgical
follow-up showed normal gastrin and chromogranin levels.
Urinary 5-HIAA level was much reduced compared to
baseline, though still marginally raised. Octreoscan showed
uptake at the liver resection margin, but no definitive lesion
was confirmed by MRI. One year later, the patient
remained asymptomatic.
Fig. 2 a Microscopic examination of the pancreatic primary, showing
well-differentiated neuroendocrine tumor with regional lymph node
involvement. The tumour cells are arranged in sheets with vascular
stroma. They have mild nuclear pleomorphism, abundant eosinophilic
cytoplasm and eccentric nuclei. Regional lymph node involvement is
present (not shown). Original magnification x400. b Immunohisto-
chemical staining of the pancreatic primary, showing positive
neuroendocrine marker synaptophysin. Original magnification x400
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The earliest presenting symptoms of functional PNETs
depend on the consequences of their hormonal output. In
gastrinomas the clinical presentation depends on the effects
of constitutive gastrin production—mainly, in historical
studies, gastric acid hypersecretion—and that of any other
gut neuropeptide(s) released. Although the classical Zol-
linger–Ellison syndrome (ZES) described multiple and/or
ectopic peptic ulcers [4, 5], a recent study showed that the
usual presenting symptoms of gastrinomas now feature
abdominal pain, diarrhea, or both in 75%, 73% and 55% of
patients respectively, with heartburn also reported in 44%
[3]. Moreover, even prior to the advent of PPI therapy, up
to 25% of malignant gastrinoma patients have no demon-
strable peptic ulceration [6].
Up to a quarter of all gastrinomas are associated with
multiple endocrine neoplasia type I (MEN 1), which is
inherited in an autosomal dominant manner. Although
gastrinoma is the most common pancreatic islet cell tumour
type in MEN 1, the most crucial component and usual
initial presentation of the syndrome tends to be primary
hyperparathyroidism, present in over 90% of MEN 1
patients [7]. Moreover, islet cell tumours in MEN 1 are
typically multiple. In view of normocalcemia, solitary
nature of the gastrinoma, lack of associated clinical features
and negative family history, the current case was considered
a sporadic occurence.
We submit that the present case illustrates the features of
a new clinical syndrome of ‘PPI-masked gastrinoma’. First,
the patient’s symptoms are predominantly not those of
hyperacidity, but rather those of hypergastrinemia—recur-
rent abdominal pain, gastrointestinal hypermotility, borbo-
rygmi, and gallbladder contraction. In contrast to historical
ZES descriptions, effective PPI-dependent suppression of
massive gastric acid hypersecretion should reduce both
peptic ulceration and diarrhea [8, 9], consistent with the
present case in which the only symptom of low gastric pH
was occasional heartburn. Indeed, omeprazole has long
been recognized to be a more tolerable and effective
therapy for gastrinoma symptoms than is the gastrin-
inhibitory somatostatin analog, octreotide [10]. Although
we would predict prominent gastric mucosal rugosity
without ulceration to be another correlate of this syndrome
[11], we have not documented this.
Second, the delay in diagnosis of this case from the time
of symptom onset is typical of PPI-masked gastrinoma.
This iatrogenic complication—in which, ironically, an
established ZES supportive therapy [12, 13]i su s e df o r
symptom relief without knowledge of the etiologic diagnosis,
culminating in eventual diagnosis of more advanced disease
with shorter average 5-year survival, perhaps reflecting a lead
time effect—should be a matter of serious professional
concern. In the present case the diagnosis of gastrinoma was
masked by PPI-dependent reversion of hyperacidity, leaving
only the nonspecific syndrome of intermittent abdominal pain
and borborygmi. Indeed, so minimally symptomatic was the
PPI-treated patient for several years that the early radiologic
detection of liver metastases was misinterpreted, and the final
diagnosis ofmalignancywas onlymadeinresponsetopainful
livercapsulardistensionbymassivetumorprogression4years
later. Since half of all ZES presentations occur in the absence
of detectable liver metastases [14], early recognition of
hypergastrinemic symptoms prior to carcinomatosis would
seem the only feasible pathway to cure.
Third, the ease of misdiagnosing PPI-masked gastrinoma
as an atypical carcinoid syndrome or even as a non-
functional metastatic PNET is well illustrated by the present
case, providing an explanation for the recent observation by
Corleto et al of declining rates of gastrinoma diagnosis
associated with rising referral rates for other PNETs.
Multiple neuropeptide hypersecretion is often seen in
neuroendocrine cancer [15]; this includes that of serotonin
production by gastrinomas [16], as well as that of hyper-
gastrinemia occurring in association with carcinoids [17]. It
follows from these observations that the heterogeneous
clinical presentations of neuroendocrine tumors could well
be explained in part by unique multi-neuropeptide signa-
tures of individual tumors. We note that a worse prognosis
has been associated with secretion of multiple neuro-
peptides by sporadic PNETs [18], further emphasizing the
hazards of late diagnosis occurring as a result of PPI-
masked symptoms.
The suboptimal sensitivity and specificity in diagnosing
pancreatic neuroendocrine tumors by conventional imaging
techniques also adds to the diagnostic dilemma. For
example, the sensitivity of MRI in detecting these tumors
is reported to vary between 29% to 57% only [19–21]. MRI
visualization of islet cell tumors, which have a rich arterial
blood supply [21], depends on their hypervascularity
relative to the surrounding normal pancreatic tissue [17],
but it is difficult to distinguish them from other vascular
lesions including hemangiomas. In the present case, tumors
already present on MRI liver in 2004 were misinterpreted
as benign hemangiomas (Fig. 1a). Curiously, FDG-PET is
reputed to be less useful in well-differentiated slow-
growing neuroendocrine tumors [18, 19] but was of value
in our case; newer positron-emitter radiopharmaceuticals
including
11C5 H T Pa n d
11C L-DOPA appear more
sensitive [20]. Somatostatin receptor scintigraphy is supe-
rior to ultrasound, CT, MRI, and FDG-PET in terms of both
sensitivity and specificity [22], though
11C 5HTP-PET may
prove even more sensitive.
In summary, the present case supports other clinical
observations [23, 24] and series [1, 25] attesting to the
evolution of a new iatrogenic syndrome caused by PPI-
90 H. Wong et al.dependent suppression of peptic symptoms. We propose a
diagnostic triad for this novel syndrome comprising (i) non-
peptic symptoms in hypergastrinemic patients receiving
maintenance PPI, (ii) late-stage presentation of metastatic
PNET, and (iii) diagnostic confusion with non-gastrinoma
PNETs. Despite the negative finding by Roy et al with
respect to diagnostic delay in PPI-treated gastrinomas
[3], we submit that this emerging entity is indeed valid,
and encourage a higher level of awareness by clinicians
using PPIs to treat chronic non-H. pylori-associated
hypergastrinemic dyspepsia, especially in middle-aged
patients with unremitting, albeit non-specific, gastrointes-
tinal symptoms.
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